Big Money Sentiment increased to 1.11 in 2018 Q3. It has change of 0.16, from 2018Q2’s 0.95. The ratio increased due to Esperion Therapeutics, Inc. positioning: 18 sold and 39 reduced. 27 funds acquired stakes and 36 increased stakes. Investors holded 26.84 million in 2018Q2 but now own 24.60 million shares or 8.34% less.
Advisory Svcs Networks Ltd Co reported 0% of its capital in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Natixis holds 0% or 7,608 shs in its capital. Stifel Corporation invested in 0% or 21,838 shs. Price T Rowe Inc Md has invested 0% of its capital in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Sectoral Asset Mngmt Inc holds 96,100 shs. Royal Natl Bank Of Canada holds 12,179 shs or 0% of its capital. Nj State Employees Deferred Compensation Plan holds 0.08% of its capital in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 11,125 shs. Vanguard has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Rhenman Asset Management Ab owns 353,961 shs. 41,500 were accumulated by Swiss National Bank. C Worldwide Group Inc A S reported 4,999 shs. 114,971 are held by Citigroup Inc. Cim Inv Mangement invested in 0.11% or 7,205 shs. Bamco Ny accumulated 100,000 shs or 0.02% of the stock. New York-based Tiaa Cref Invest Mngmt Limited Company has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Earnings report for Esperion Therapeutics, Inc. (NASDAQ:ESPR) is awaited on February, 19., as reported by Faxor. Analysts predict $-1.33 EPS. That’s $0.11 up or 7.64 % from 2018’s earnings of $-1.44. Analysts at Wall Street see Esperion Therapeutics, Inc.’s -28.49 % EPS growth compared to $-1.86 EPS for previous quarter. Ticker’s shares touched $45.5 during the last trading session after 2.36% change.Currently Esperion Therapeutics, Inc. is downtrending after 3.18% change in last February 7, 2018. ESPR has also 221,677 shares volume. ESPR underperformed by 3.18% the S&P500.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Total analysts of 3 have positions in Esperion Therapeutics (NASDAQ:ESPR) as follows: 2 rated it a “Buy”, 1 with “Sell” and 0 with “Hold”. The positive are 67%. Since August 17, 2018 according to StockzIntelligence Inc Esperion Therapeutics has 3 analyst reports. In Friday, August 17 report Citigroup upgraded the stock to “Buy” rating.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol .The company has $1.22 billion market cap. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study.Currently it has negative earnings.

For more Esperion Therapeutics, Inc. (NASDAQ:ESPR) news posted recently go to: Seekingalpha.com, Nasdaq.com, Seekingalpha.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Three sell-siders bullish on Kodiak Sciences in premarket analyst action – Seeking Alpha” posted on October 29, 2018, “Notable Thursday Option Activity: ESPR, ADBE, RGLD – Nasdaq” on December 20, 2018, “Esperion up 8% premarket – Seeking Alpha” with a publish date: October 26, 2018, “Esperion Therapeutics halted pending news – Seeking Alpha” and the last “ESPR Makes Bullish Cross Above Critical Moving Average – Nasdaq” with publication date: November 02, 2018.